Iclusig Approved for Rare Leukemias

FRIDAY, Dec. 14 (HealthDay News) -- Iclusig (ponatinib) has been approved by the U.S. Food and Drug Administration to treat two rare forms of leukemia -- cancers of the blood and bone marrow.

The drug was sanctioned for adults with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), the FDA said Friday in a news release.

Iclusig blocks the effects of proteins that promote development of cancer cells, the agency said. The drug was granted accelerated approval following a single study of 449 people with either CML or Ph+ ALL.

The product's label will include a boxed warning that users are at heightened risk of blood clots and liver poisoning. More common but less serious clinical side effects included high blood pressure, rash, abdominal pain, fatigue, headache, dry skin, constipation, fever, joint pain and nausea.

Iclusig is marketed by Ariad Pharmaceuticals, based in Cambridge, Mass.

More information

The FDA has more about this approval.

-- Scott Roberts

Copyright © 2012 HealthDay. All rights reserved.

We'd like your feedback.

Are you a cancer patient, cancer survivor or a caregiver for a cancer patient? Please complete a very brief survey to improve patient care.

Thank you!

A survey will be presented to you after you finish viewing our Leukemia content.


Take a Personalized Health Test